Symons Capital Management’s Gilead Sciences GILD Stock Holding History

Symons Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$6.44M	Sell	92,230 -6,881	-7%	-$483K	4.13%	4
2021 Q2	$6.83M	Sell	99,111 -4,449	-4%	-$297K	3.89%	5
2021 Q1	$6.69M	Sell	103,560 -13,773	-12%	-$888K	3.5%	7
2020 Q4	$6.84M	Buy	+117,333	New	+$7.08M	3.77%	8
2020 Q2	–	Sell	-91,412	Closed	-$6.83M	–	86
2020 Q1	$6.83M	Buy	+91,412	New	+$6.32M	4%	5

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Symons Capital Management's GILD Position: Q3 2021 in Review

Symons Capital Management reduced its Gilead Sciences (GILD) stake by 6.9% in Q3 2021, selling an estimated $483K and leaving 92,230 shares worth $6.44M. The position accounts for 4.13% of the portfolio, ranked #4.

Symons Capital Management first reported a position in GILD in Q1 2020 and has held it in 5 quarters since. The position peaked at $6.84M in Q4 2020. 1,564 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

Symons Capital Management held 92,230 shares of Gilead Sciences worth $6.44M as of Q3 2021.
Symons Capital Management sold 6,881 Gilead Sciences shares in Q3 2021, an estimated $483K.
Gilead Sciences made up 4.13% of Symons Capital Management's portfolio in Q3 2021, its #4 holding.
Symons Capital Management first reported a position in Gilead Sciences in Q1 2020 and has held it in 5 quarters since.
Symons Capital Management's Gilead Sciences position peaked at $6.84M in Q4 2020.
1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Symons Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.